SeekingAlpha · Aug 8, 2026
PG
NASDAQ · PGEN
Precigen, Inc.
Healthcare · Biotechnology
$6.95
Down-$0.24 (-3.34%)
Updated Aug 31, 2026, 12:55 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.09B
- P/E ratio
- -2.51
- Dividend yield
- 0.00%
- 52-week range
- $2.99 – $7.72
- Volume
- 2.7M
- Avg. volume
- 4.88M
Price performance
PGEN price history
1M range · 0 trading sessions · Daily adjusted prices
PGEN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PGEN news
The latest Smart Investors Daily articles mentioning PGEN.
Stock researchCompany · Overview
PGEN research
Overview
Company profile and research snapshot.
Company profile
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | Citizens | Market Outperform | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement
Precigen stock is upgraded to Strong Buy as PAPZIMEOS revenues are up after FDA approval for RRP. Learn PGEN's Q2 profitability, catalysts, and EMA upside.
Benzinga · Aug 5, 2026
Toast To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts changed outlook on top names. UBS cut Fidelity National Information target, JP Morgan downgraded Ball, Needham raised Hinge Health.
Benzinga · Aug 5, 2026
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $14 to $18.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
